Delivery Order SPE2DR25D2005-SPE2DR26FE8R0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,853.05 to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. This firm fixed-price, non-set-aside contract specifies performance through AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December 2, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $6,360.82 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on November 26, 2025, with completion targeted for November 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will...
- The Defense Logistics Agency awarded a delivery order valued at $16,903.16 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injections on December 10, 2025, with an ultimate completion date of December 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $33,236.84 and is scheduled for completion by August 7, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child...
- The Defense Logistics Agency awarded a $7,124.96 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on December 9, 2025, with completion scheduled for December 10, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a delivery order valued at $26,577.38 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections on December 5, 2025, with completion targeted for December 8, 2025. This non-competitive delivery order represents a firm fixed price transaction executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.999 billion through December...
- The Defense Logistics Agency awarded a $35,751.17 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $39,293.33 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pens on November 18, 2025. This firm fixed-price, non-set-aside contract calls for delivery to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a completion date of November 19, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,537.40 on June 2, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $8,047.44 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections on November 14, 2025, with an ultimate completion date of November 17, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite...
- SPE2DR25D2005Indefinite Delivery Contract
- SPE2DR25D2005-SPE2DR26FE8R0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,251.71 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on December 11, 2025, with completion scheduled for December 12, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a broad spectrum of medications and medical commodities to support federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This specific order for Zepbound, a GLP-1 receptor agonist diabetes medication, reflects the contractor's role in delivering specialty pharmaceuticals to military and veteran healthcare operations. The company's extensive portfolio of federal awards demonstrates consistent capability to fulfill diverse medical supply requirements through competitive procurement, with delivery orders typically structured under firm fixed-price arrangements ranging from minimal to substantial transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 12/10/25 |